áøåø ùìà öôéú áøàéåï äîñáéø áîôåøù îä úäìéê ä"áéãåã", îäí äöéìåîéí (äðôùä àå àì÷èøåðé) åë'åðëúá áî÷åø òì éãé JohnnyDough
áî÷åí æä àúä áåçø ìùìùì îäôä ñéñîàåú ðáåáåú ùì ä WHO ëîå úåëé.
àúä âí îúòìí îäòåáãä ùáøçáé äòåìí àðùéí ù÷éáìå ÷ðñ òì îñéëä - äìëå ìáéú äîùôè åãøùå äåëçä ì÷éåí äååéøåñ áâéðå ÷éáìå ÷ðñ - åæëå
ä"ååéøåñ" ìà áåãã. âí áàøõ äåâùä á÷ùä øéùîéú îñåãøú îîèøã äáøéàåú ìñô÷ äåëçåú ì÷éåí äååéøåñ - æä ðâøø ëáø ùðä åçöé.
àðé îðéç ìöòøéùâí àéúê äãéåï îñúééí ëàï.
çáì, àúä ðùîò áçåø àéðèéìéâðè.
àâá àéðèéìéâðöéä áçáøä ùìé òåáãéí úåúçéí áúçåí äîéçùåá, îëôéìé îèøéöåú úåê ùéðä åâåæøé ðâæøéí ìúéðå÷åú ùìäí.
àéê àðùéí ùëìúðéí ëîåäí åáëì äòåìí áìòå àú äìå÷éùéí äîâåçëéí ùì îñéëåú ñâøéí åáåñèøéí - æä àðé ìà îöìéç ìäáéï.
Complete Genome Sequence of a 2019 Novel Coronavirus (SARS-CoV-2) Strain Isolated in Nepal -
https://journals.asm.org/doi/10.1128/MRA.00169-20
Severe acute respiratory syndrome coronavirus 2 isolate SARS-CoV-2/human/NPL/61-TW/2020, complete genome -
https://www.ncbi.nlm.nih.gov/nuccore/MT072688
÷àæ úåëì ìúøâí ìé? ðâéã àú äôéñ÷ä äáàä îäîáåàä ùìê?
àí àúä îöèè îùäå áååãàé ùàúä éëåì éåúø ìäñáéø îä äáàú ìðå
àðé ø÷ çéôùúé àú äîçøåæú "Illumina MiSeq system with the Burrows-Wheeler Aligner MEM algorithm" îäîáåàä ùìê åäâòúé ìàéê ìäøéõ áìéðå÷ñThe specimen tested positive for SARS-CoV-2 by real-time reverse transcriptase PCR (rRT-PCR) developed in the University of Hong Kong (5). Sequencing was done using the Illumina MiSeq system with the Burrows-Wheeler Aligner MEM algorithm (BWA-MEM) 0.7.5a-r405 assembly method. The full genome was amplified directly from the RNA extract from the original specimen using gene-specific primers for open reading frame 1b (ORF1b) and N (Table 1) to produce overlapping PCR products covering the full genome (5). The expected amplicon sizes of the ORF1b and N gene assays are 132 bp and 110 bp, respectively (5). The raw reads were first cleaned by trimming low-quality bases with Trimmomatic 0.36 (-phred33, LEADING:20, TRAILING:20, SLIDINGWINDOW:4:20, MINLEN:40). The new genome sequence was obtained by first mapping reads to a reference SARS-CoV-2 genome using BWA-MEM 0.7.5a-r405 with default parameters to generate the consensus sequence. In addition, the assembly produced by MEGAHIT 1.2.9 (de novo assembly), using default parameters, was used to cross-validate with the reference-based method as an internal control. The two results were consistent, and our final sequence is based on the reference-based method. The reference sequence we used was from the Global Initiative on Sharing All Influenza Database (GISAID; strain identifier EPI_ISL_405839). The reads mapped to the reference sequence were then curated in a pileup alignment file to obtain the consensus sequence (minimum coverage threshold, 10). FastQC 0.11.8 was used to assess the sequence quality before trimming and after alignment to prevent potential errors. There were 5,246,584 paired-end sequences in the raw data. A total of 9,891,431 records were included in the reference-based alignment after trimming, and 9,887,093 (99.96%) of them were mapped to the SARS-CoV-2 reference genome.
TABLE 1
TABLE 1 Gene-specific primer and probe sequences used
Gene Primera ORF1b     Forward 5′-TGGGGYTTTACRGGTAACCT-3′     Reverse 5′-AACRCGCTTAACAAAGCACTC-3′     Probe 5′-TAGTTGTGATGCWATCATGACTAG-3′b N     Forward 5′-TAATCAGACAAGGAACTGATTA-3′     Reverse 5′-CGAAGGTGTGACTTCCATG-3′     Probe 5′-GCAAATTGTGCAATTTGCGG-3′b
a
Y is C or T; R is A or G; W is A or T.
b
In 5′-6-carboxyfluorescein/ZEN internal quencher/3′-Iowa Black fluorescent quencher format.
We generated a consensus sequence of 29,811 bp with no gap and high average coverage (>77,000ª). Primer binding sites at the 5′ and 3′ ends were removed, resulting in this genome being 59 nucleotides (nt) shorter than a reference genome in GenBank (accession number NC_045512), excluding the poly(A) tail of the genome.
For phylogenetic analyses, SARS-CoV-2 full-genome sequences were aligned with CLUSTAL W (6) using MEGA 10.0.5. (7). The new SARS-CoV-2 sequence was compared to existing genomes using online NCBI BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi).
Full-genome comparison of the isolate revealed >99.99% identity with two previously sequenced genomes available at GenBank (MN988668 and NC_045512) for SARS-CoV-2 from Wuhan, China, and >99.9% with seven additional sequences (MN938384.1, MN975262.1, MN985325.1, MN988713.1, MN994467.1, MN994468.1, and MN997409.1). The final genome of sequenced SARS-CoV-2 consists of a single, positive-stranded RNA that is 29,811 nucleotides long, broken down as follows: 8,903 (29.86%) adenosines, 5,482 (18.39%) cytosines, 5,852 (19.63%) guanines, and 9,574 (32.12%) thymines.
The sequence of BetaCoV/Nepal/61/2020 from coordinates 1 to 29811 is identical to the sequence of isolate 2019-nCoV WHU01 (GenBank accession number MN988668) from 15 to 29825 (29810/29811), except at site 24019, with a substitution of a C, from 2019-nCoV WHU01, for T. The sequence of BetaCoV/Nepal/61/2020 from coordinates 1 to 29811 is identical to the sequence of isolate Wuhan-Hu-1 (GenBank accession number NC_045512) from 16 to 29826 (29810/29811), except at site 24019, with the same substitution of a C from isolate Wuhan-Hu-1 for T.
The C24019T mutation corresponds to C24034T if we use the sequence located under GISAID strain identifier EPI_ISL_405839 as a reference. This was a silent mutation at the spike gene (codon AAC to AAT). Based on the reference sequence, the following five mutations were also identified: T8782C (in ORF1a, codons AGT to AGC, silent mutation), T9561C (in ORF1a, codons TTA to TCA, nonsilent mutation), C15607T (in ORF1b, codons CTA to TTA, silent mutation), C28144T (in ORF8b, codons TCA to TTA, nonsilent mutation), and T29095C (in nucleocapsid, codons TTT to TTC, silent mutation).
Additional epidemiological and clinical features of this case of COVID-19 were reported in reference 4.
Data availability.
This sequence has been deposited in GenBank under the accession number MT072688 and at the GISAID EpiCoV newly emerging coronavirus SARS-CoV-2 platform under identifier EPI_ISL_410301. The accession numbers for the Illumina MiSeq sequence raw reads in the NCBI Sequence Read Archive (SRA) are PRJNA608651 (BioProject), SRP250653 (SRA), SAMN14180202 (BioSample, BetaCoV/Nepal/61/2020), SRX7798477 (SRA; GISAID EPI_ISL_410301), and SRR11177792 (run, WHV-Nepal-61-TW_1.fastq.gz).
ùæä áäçìè î÷ãí àú ëåìðå ìàï ùäå
ðòøê ìàçøåðä òì éãé NAOR2207; 01-02-2023 áùòä 09:24.
àå÷éé ùàìúé àú AI - çøà áìáï
Describe how covid-19 has been isolated in simple words ?
Covid-19 is a virus that is spread from person to person through respiratory droplets when an infected person talks, coughs or sneezes. To prevent the spread of the virus, people can take various measures such as wearing masks, washing their hands frequently, practicing social distancing, and avoiding large gatherings. Additionally, people who have symptoms or have been in close contact with someone who has tested positive for Covid-19 are usually isolated, meaning they stay at home or a designated facility away from others, to avoid infecting others.
how covid-19 has isolated ?
Covid-19 has caused widespread isolation globally due to the measures put in place to control its spread. These measures include:
Quarantine: People who have tested positive for Covid-19 or have been in close contact with someone who has tested positive are required to stay at home for a designated period of time.
Social distancing: People are encouraged to maintain a safe distance of at least 6 feet from others in public spaces to reduce the risk of transmission.
Remote work: Many companies have implemented remote work policies to reduce the number of people in the workplace and slow the spread of the virus.
School closures: Schools and universities have been closed in many countries, leading to virtual learning and limiting in-person interactions between students.
These measures have resulted in people spending more time alone or with only their immediate family, reducing opportunities for social interaction and increasing feelings of loneliness and isolation.
ôøéöú ãøê îãòéú!!!
àéê æä îú÷ùø ì"ååéøåñ" ëùîéï äéãåòåú ìàìåäé îãòðé äáòì ùååéøåñ àéðå ééöåø çé åìëï àéï ìå DNA (àìà ùáøéøé DNA, àåìé, áîø÷) -Illumina MiSeq system with the Burrows-Wheeler Aligner MEM algorithm
The Illumina MiSeq system is a high-throughput sequencing platform that is used for DNA and RNA sequencing. It uses a technology called Next-Generation Sequencing (NGS) to generate large amounts of sequence data.
The Burrows-Wheeler Aligner (BWA) MEM algorithm is a popular software tool used to align sequencing reads to a reference genome. It is used to map the short sequencing reads generated by NGS platforms like the Illumina MiSeq to a reference genome, allowing for the identification of genetic variants and mutations. The BWA-MEM algorithm is highly accurate and efficient, making it a popular choice for genome analysis.
In combination, the Illumina MiSeq system and the BWA-MEM algorithm provide a powerful tool for genetic research and the study of diseases like Covid-19. They can be used to sequence the viral genome and identify genetic mutations, which can inform the development of diagnostic tests and treatments.
ìîãòðé äñôâèé äôéúøåðéí
àðé îëéø àú äúäìéê ùáå îáåããéí åéøåñéí åâí áåããå àú äåéøåñ äðåëçé (âéãåì áúøáéú ùì úàé vero åñéðåï áôéìèøéí öôåôéí ùîôøéãéí áéï äúàéí ìáéï äåéøåñéí). æä úäìéê ñèðãøèé ìçìåèéï ùîùîù áîùê òùøåú ùðéí.áøåø ùìà öôéú áøàéåï äîñáéø áîôåøù îä úäìéê ä"áéãåã", îäí äöéìåîéí (äðôùä àå àì÷èøåðé) åë'å
áî÷åí æä àúä áåçø ìùìùì îäôä ñéñîàåú ðáåáåú ùì ä WHO ëîå úåëé.
àúä âí îúòìí îäòåáãä ùáøçáé äòåìí àðùéí ù÷éáìå ÷ðñ òì îñéëä - äìëå ìáéú äîùôè åãøùå äåëçä ì÷éåí äååéøåñ áâéðå ÷éáìå ÷ðñ - åæëå
ä"ååéøåñ" ìà áåãã. âí áàøõ äåâùä á÷ùä øéùîéú îñåãøú îîèøã äáøéàåú ìñô÷ äåëçåú ì÷éåí äååéøåñ - æä ðâøø ëáø ùðä åçöé.
àðé îðéç ìöòøé
çáì, àúä ðùîò áçåø àéðèéìéâðè.
àâá àéðèéìéâðöéä áçáøä ùìé òåáãéí úåúçéí áúçåí äîéçùåá, îëôéìé îèøéöåú úåê ùéðä åâåæøé ðâæøéí ìúéðå÷åú ùìäí.
àéê àðùéí ùëìúðéí ëîåäí åáëì äòåìí áìòå àú äìå÷éùéí äîâåçëéí ùì îñéëåú ñâøéí åáåñèøéí - æä àðé ìà îöìéç ìäáéï.
æå âí ìà äôòí äøàùåðä ùàðé ðú÷ì áèéòåðéí äàìä, äí ôùåè ìà ðëåðéí áìé ÷ùø ìèòðåú äðëåðåú ùéù ìê áéçñ ìîèøã äúçìåàä åììåáé äáéðìàåîé ùì äáéâ ôàøîä. àúä éëåì ìà ì÷áì àú äãáøéí ùìé áòðééï, ëîå ùàúä éëåì ìà ì÷áì àú äãáøéí ùì ùîåàì ùôéøà áòðééï (https://twitter.com/shmuelcshapira/s...65468412698628) ìîøåú ùâí äåà ìà çùåã áúåø áåè ùì ùøåï ôøééñ åñðèä ÷ìàåñ, àáì áéï æä ìáéï ìùìùú éåðéí, ùðäáéí, ÷åôéí åúåëééí ôòåø âéà öìîååú.
äùëìä äéà îìëúçéìä îãã çìù éçñéú ìàéðèéìéâðöéä åëùàúä ôåøè ìàðùéí òì ðéîé äôçã äôøèééí ùìäí àæ äàéðèéìéâðöéä îàåôñðú ááâàæ× ìèåáú îãéãú àåøê äàó.
áñäØë îä ùàðé àåîø, äCHATGPT æä áåìùéè
ðééñ! àðé îøâéù ëîå ùéçåú äùìåí áäñëîé àåñìå. éù äú÷ãîåú!
ø÷ ìîä àðé îøâéù ëîå òøôàú ?
ùîú ìéð÷ ìèåééèø òí ùù úâåáåú ? àúä øöéðé?
àðé ÷åãí ëì ÷åøà àú äúâåáåú, æä ëîå äáîàçåøä ùì äñôø
https://twitter.com/OsNetDailyNews/s...23402803306509
àí àúä îøâéù ëîå òøàôú, æä ëðøàä áâìì ùàúä îçôù ìøéá ëì äæîï òí ëåìí.
äáàúé ìéð÷ ìèååéèø ùì àçú äãîåéåú äáëéøåú áéåúø áéùøàì áúçåí äøôåàä/áøéàåú öéáåø/èéôåì áîùáøéí ùâí ðéäì áîùê äøáä ùðéí àú äîëåï äáéåìåâé áðñ öéåðä.
äáàúé àåúå îùåí ùùéèåè ÷ìéì áôøåôéì ùìå éáäéø ìê ùäåà îîå÷í ÷øåá îàåã àìéê áëì îä ù÷ùåø ìôñèéáì ä÷åáéã äòåìîé åäî÷åîé, òì ùåøú îøëéáé äôåìçï ùìå, òí ãâù îéåçã òì ðåæì ä÷åãù äáåøìàé.
ùåàå îé ãä ååéøåñ !!!!
áå÷ ùìí ùì îø÷ ëìéåú ÷åôéí åøå÷ ùì ôøåú áúøáéú
ìøàåú àú äååéøåñ áîé÷øåñ÷åô àì÷èøåðéí, æä ìà àåîø ìæäåú àåúå áååãàåú. ëãé ìåîø ùøåàéí àú äååéøåñ äæä áååãàåú, òåùéí àú äúäìéê ùäåà äñáéø, ùæä ì÷çú åéøåñ îáåãã åúàéí ð÷ééí åìúú ìååéøåñ ìòáåã òì äúàéí äàìå åàæ î÷áìéí äøáä çåîø åéøàìé îúçú ìîé÷øåñ÷åô. àí ì÷çðå åéøåñ ÷åøåðä, àæ àðçðå éåãòéí ùàðçðå îñúëìéí åéøåñ ä÷åøåðä åìà òì åéøåñ àçø.
äúäìéê ùäåà úàø ùí äåà úäìéê øâéì ìâîøé, ìà ééçåãé áëìì ì÷åøåðä. àí äåà ìà î÷áì àú æä, àæ äåà ìà î÷áì ùåí úîåðä ùì ùåí åéøåñ åäåà ñúí îôæø òùï.
ëãé ìæäåú ùùðé àðùéí äí àçéí, áåã÷éí ÷øáä âðèéú áðéäí åáéï ääåøéí. úîåðä ìà îñôé÷ä. àåúå äãáø òí äååéøåñ, äæéäåé äååãàé äåà âðèé áPCR åæéäåé î÷èòéí ñôöéôééí ìîùôçä. úîåðåú îìîãåú åéøåìåâéí àéôä åàéê äååéøåñ îúôúç. åàçøé äåñôú öáòéí, âí éôåú ìôøñåí. àéèé, é÷ø åçñø îùîòåú áøîú äæéäåé.
ìà ñåø÷éí àú ãâéîú äî÷åø, ëé äéà áëîåú ÷èðä îàåã, àáì âí éãåòä ìøîú äðå÷ìàåèéã. îâãìéí àú äååéøåñ áúàéí åàæ äëîåú ùì äçåîø äååéøàìé òåìä. áâìì ùæä ìà äî÷åø, àìà úøáéú, àæ éù áå ëîä îåèöéåú ìòåîú äî÷åø.
àôùø ìäùúîù ááéåôñéä îáðé àãí áùáéì äúîåðåú, àáì öøéê éåúø àéùåøéí åâí àðùéí ùîöáí äøôåàé äéä âøåò áîéåçã.
ìîùì ôä: https://bmcgastroenterol.biomedcentr...05-3/figures/2
åäîàîø äæä, ùîæäéø îôðé æéäåé ùâåé ùì äååéøåñ ëàùø äãâéîä îàãí åìà úøáéú, åîöéò ëîä ð÷åãåú ìååéãåà ùàëï îãåáø áååéøåñ ä÷åøåðä: https://journals.lww.com/JASN/Fullte...ectron.30.aspx
äçæøä ùìå òì äðéñåé, îåëéçä àú äð÷åãä ùäáàúé ìòéì. úîåðä ìáã ìà áäëøç îñôé÷ä. çééáéí âí øéöåó RNA. áòé÷ø àí àéï äéëøåú òí äîåøôåìåâéä äñôöéôéú ùì äååéøåñ.
àí é÷çå ìéçä îòùøú àìôé çåìé ÷åøåðä, æä ìà éòæåø äøáä, ëé éù äøáä çåîø åéøàìé áäøáä çåîø ìà åéøàìé. æä ìà îùôø àú éçñ äàåú ìøòù.
æä åéøåñ åìà çééã÷. àé àôùø ìáåãã àåúå áàîöòåú äáãìé îñä. ìîéèá éãòúé, àé àôùø ìñîï àåúå áöáò. åäåà ìà éúøáä áìéçä, ëé äåà öøéê úàéí çééí.
äãåâîàåú ùì äèøîéèéí åäôàæì ôùåè ìà ðëåðåú.
àéï ìé àéê ìú÷ï àú äãåâîä ùì äèøîéèéí ëé îîù øçå÷ä îàééê ùPCR òåáã. ðëåï, àôùø òí PCR ìáðåú ëì ãáø ùøåöéí. àáì á35-40 îçæåøéí, ìà ðéúï ìáðåú ùåí ãáø áòì îùîòåú, àìà àí äåà îúàéí ìî÷èòéí ùîçôùéí. åàæ áåã÷éí àú éçñ äàåú ìøòù. ëîä çåîø ÷éáìðå, áð÷åãåú éãåòåú, áéçñ ìPCR àçø ùøõ áúðàéí î÷áéìéí. àí äúâìä çåîø áð÷åãåú ìà öôåéåú, àå áãâéîú äáé÷åøú, àæ éåãòéí ùîùäå äùúáù. îä äñéëåé ìáðåú î÷èò åéøåñ ÷åøåðä á35-40 îçæåøéí ììà çåîø åéøàìé? ôçåú ñáéø î10 ôòîéí øöåó ùù-ùù.
äøéöåó ùì äååéøåñ ìà ãåîä ìôàæì, àáì ôä éù ìé àéê ìú÷ï àú äîùì, ëãé ùéúàéí ìîöéàåú.
úçùåá òì ëîåú âãåìä ùì ôàæìéí æäéí, ùëì àçã îäí ìà ìâîøé îôåø÷. àôùø ìñãø àåúí ëê ùðìîã îäî÷èòéí äùìîéí áàçã, ëãé ìáðåú àú äùðé. òåùéí àú æä òí îçùá, ëé æå ëîåú âãåìä îàåã ùì ôàæìéí. éù òåã úðàéí ùðéúï ìäöéá, ëãé ìäéîðò îèòåéåú, ëîå âåãì ñåôé öôåé.
âí ôä, éù ìã"ø áòéä òí äîúåãä äîãòéú áëìì. äîúåãåú äàìå ìà ñôöéôéú ì÷åøåðä.
áçì÷ äùðé ùì äñøèåï äåà àéáã àåúé ìâîøé.
äåà îèéì ñô÷ ááéåìåâéä äîåì÷åìøéú áëìì, àåçæ àú äçáì îùðé ÷öåúéå. äèëðåìåâéä ìà ðëåðä, àáì îàôùøú ìùìåè áðå áàîöòåú úùãåøåú àì÷èøåîâðèéåú?
îúçéì ìãáø òì úùãåøåú àì÷èøåîâðèéåú áéï àðùéí åäñáéáä, ùDNA áðåé áöåøä àçøú îîä ùäîãò çåùá, ùDNA äåà àðèðä, ùòåæøú ìú÷ùø åìäúîöà áñáéáä. åæä àîéúé åòì æä àéï ìòøòø. åàéï ìæä ùåí ñéîåê îãòé.
MRI ìà ÷åìè úùãåøåú îäâåó áîåáï ùäåà îúééçñ àìéå. äåà "îëøéç" îåì÷åìåú áâåó ìùãø åîäúùãåøú äæå äåà îôé÷ àú ääãîéä.
àðé éåãò ùDNA åRNA ÷åìèéí èåá ÷øðé øðèâï åæä ùåáø àåúí ìôòîéí. 5G? îîù ìà áñãø äâåãì äøìååðèé ìîåì÷åìú äDNA åì÷ùøéí ùìä. äëì áðôðåôé éãééí, òí àôñ äåëçä ù÷ùåøä ìú÷ùåøú, úàåí òëáåú, úàåí àåøê âì åöåøú àðèðä, äðçúåú òì ø÷îåú åòåã ðåùàéí øìååðèééí ìúàåøéä ùìå.
âí äúøâåí ùìå ìî÷åø äùí øéáåæåí, ìà ðëåï. äåà öåã÷ ùñéåîú àëï ÷ùåøä ìâåó äúà, àáì äúçéìéú îîù ìà ÷ùåøä ìöìò. æä ùéáåù ùì ùí äîàëì ùîîðå äôé÷å àú äçåîø.
îä ùøùîúé î÷åãí, âéãåì úøáéú åéøàìéú áúàé vero.
áå÷ ùîöéâ àú äåéøåñ áëì ùìáé ääãá÷ä - îäçãéøä ìúàéí, ãøê äùëôåì ùìå åëìä áùçøåø ùì äòåú÷éí äøáéí.
ìîòï ääâéðåú àåîø ùàðé ìà áîöá øéëåæ ëøâò ì÷øåà (áàîú) àú úâåáúå ùì mk4th
åáèç åáèç ùàðé ìà îâéò îäúçåí äð"ì, ëê ùúùåáä î÷öåòéú òí èéòåðéí ñåúøéí îîðé úäéä ëéùìåï éãåò îøàù.
àáì ìà æðçúé àú äòðééï. åìà äúòìîúé îäúùåáä ùì mk4th
áðúééí àðé îçôù ñéîåëéí ìãáøéé áãáø äàðùéí àùø æëå áîùôèéí äéåú åäååéøåñ ìà áåãã,
åâí àñéè àú äãéåï ìðéñéåï ùìé (àí ìâ'åðé îåúø, áòðééï ääãá÷åú äîùôçä ùìå, àæ âí ìé)
ðâéã ìèèðåñ.
îòì òùøéí ùðä ìà ãçôúé àú äùèåú äæå ìâåó ùìé, åðçúëúé ìà ôòí çúëéí îëåòøéí òí äîåï ãí îáøæìé áðééï çìåãéí, àñôìè îâ'åééó åùàø îøòéï áéùéï.
ùìà ìãáø òì äôôéìåîä ùãçôå ñúí ëëä ìàçééðéí ùìé ëùäéå áâéì îöååä.
àáì ðçæåø ìäúî÷ã áååéøåñ äëì ëê îãá÷ - îâéôú ÷õ äàðåùåú.
(ôä äúçìúé ìëúåá òìéé àéùéú, àáì îç÷úé)
äáçåø ùàåñó îîðé àú ôçéåú äáéøä (àéù áï ùîåðéí/úùòéí á÷åùé äåìê åàéï ìå îåùâ îä æä î÷ìçú) áùéà ä÷åøåðä äéä îçèè áæáì, ìà îñéëä åìà áèéç,
åàæ äéä áà àìééåäééúé îåñø ìå áìé ëëôåú àå îñøéçä áëéó àú ù÷éåú äðéìåï òí äôçéåú, éã ðåâòú áéã, åàçø ëê äééúé îâøã àú äòéðééí àå îùäå.
á÷éöåø áãéçä, àáì úðå ìé ÷öú æîï ìäúàøâï òì úùåáä äåìîú.
àðé àéèé áîçùáåú ìòú æé÷ðä.
äøùàåú ôøñåí
öéèåè ääåãòä áúâåáä